Insmed reported $120.96M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
BioMarin Pharmaceutical USD 1.38B 42M Sep/2025
Cytokinetics USD 0 0 Dec/2023
Dynavax Technologies USD 73.29M 2.4M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Insmed USD 120.96M 13.36M Sep/2025
Novartis USD 6.42B 114M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Sarepta Therapeutics USD 1.08B 83.13M Sep/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.63B 127.5M Sep/2025